Phase II trial of recombinant tumor necrosis factor in disseminated malignant melanoma

E. R. Feldman, E. T. Creagan, D. J. Schaid, D. L. Ahmann

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Abstract

Twenty-one patients with disseminated malignant melanoma received recombinant tumor necrosis factor (TNF), 150 μg/m2 intravenously on days 1- 5 every 2 weeks for four cycles and then every 3 weeks. Recombinant TNF produced no meaningful palliation. One patient (5%) attained an objective response of nodal, but not visceral, disease, which lasted 3 weeks. The median time to progression was 4 weeks. The median survival was 7.7 months. Ninety percent of patients developed mild to severe cytokine 'flu.' Ten percent developed significant hepatic toxicity (AST > 3 times normal). As a single agent, recombinant TNF is not likely to palliate disseminated malignant melanoma. However, combinations of recombinant TNF and cytotoxic or immune modulatory agents, particularly gamma interferon, may merit further investigation.

Original languageEnglish (US)
Pages (from-to)256-259
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume15
Issue number3
DOIs
StatePublished - Jan 1 1992

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II trial of recombinant tumor necrosis factor in disseminated malignant melanoma'. Together they form a unique fingerprint.

Cite this